At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

US pharma major Merck (NYSE: MRK) has reported a Phase III success for Welireg (belzutifan) plus Keytruda (pembrolizumab) as ...

The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell ...

Arcus Biosciences (NYSE:RCUS) reported positive late stage efficacy results for casdatifan, its investigational HIF-2a inhibitor, in late line renal cell carcinoma. The company released biomarker ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

Earlier analyses demonstrated strong local tumor control, with nearly nine in 10 patients remaining free of recurrence at ...

KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...

In the absence of trials, a post hoc analysis compared stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy (HDR-BT) in intermediate-risk prostate cancer.

Study of late toxicities of chemotherapy regimens in testicular cancer survivors shows that higher cisplatin doses link renal impairment to increased heart health risks.

Belzutifan-lenvatinib slows progression versus cabozantinib with much longer response dura ...

Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

A large national study in Denmark following nearly 1,900 patients over almost a decade has found that a minimally invasive ...